P-212 - POPULATION PHARMACOKINETICS OF SASANLIMAB IN PATIENTS WITH SOLID TUMORS: MODELING-BASED ANALYSIS OF DATA FROM THE FIRST-IN-PATIENT TRIAL.
L. Zhou1, K. Liao2, D. Yin1, X. Chen3, J. Masters1; 1Pfizer Inc., San Diego, CA, USA, 2Arcus Biosciences, Hayward, CA, USA, 3Erasca, Inc., San Diego, CA, USA.